ClinicalTrials.gg

Program

HUC1-394

Its studies are mostly in Dry Eye Syndromes, led by Huons Global.

Furthest: phase 2, since Jun 16, 20261 company-led study, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huons Global11 open or runningphase 2since Jun 16, 2026Jun 16, 2026Jun 2027phase 2 · NCT07656688

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2026First study: phase 2 study in Dry Eye SyndromesFirst studyNCT07656688 · 150 planned · South Korea

Ahead

  1. Jun 2027Primary completion: phase 2 study in Dry Eye SyndromesNCT07656688

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07656688Dry Eye Syndromes · South Korea2RecruitingJun 2027150

How it is read

Names in the registry

  • “HUC1-394”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
HUC1-394 (Huons Global): development program | ClinicalTrials.gg